Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Jefferies Financial
JEF
5
Amazon
AMZN
US OptionsDetailed Quotes
CHRS250516P1500
- 0.50
- 0.000.00%
15min DelayTrading Apr 24 13:29 ET
0.00High0.00Low
0.00Open0.50Pre Close0 Volume3 Open Interest1.50Strike Price0.00Turnover112.62%IV-0.70%PremiumMay 16, 2025Expiry Date0.51Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9328Delta0.5672Gamma1.99Leverage Ratio-0.0008Theta-0.0004Rho-1.85Eff Leverage0.0003Vega
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Coherus BioSciences Stock Discussion
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
Monday, 28th April at 10:10 am
– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab –
– Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with tori...
Bloody shit. They just want to buy low before reset the actual PT of $7
Coherus Lands Massive $558M Deal: Strategic Pivot to Oncology Extends Cash Runway to 2027
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
Coherus BioSciences (NASDAQ: CHRS)has announced plans to repurchase approximately $170 million of its 1.500% Convertible Senior Subordinated Notes due 2026 through privately negotiated transactions. The repurchase will be executed at 100% of principal amount plus accrued interest.
The repurchase is contingent on the closing of the previously announced UDENYCA franchise divestiture t...
Coherus Unveils Massive $230M Debt Reduction Plan, Starting With $170M Note Buyback
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture –
Breakthrough Cancer Treatment Data: Coherus' CCR8 Antibody Shows Promise in Head & Neck Cancer Trial
Upon the completion of the Udenyca divestiture and pay-off of our significant debt and royalty obligations, we are projecting a cash position of approximately $250 million,” Coherus CEO Denny Lanfear said in the release. “These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026.”
This clinical-s...
No comment yet